Core Insights - Biogen is focused on rebuilding the company and expanding its portfolio over the next five years, aiming to create shareholder value through strategic growth initiatives [1] - The company has significantly increased its late-stage pipeline, now boasting 10 Phase III programs, with the first results expected this year and subsequent data releases planned annually through the end of the decade [1] - Biogen has managed to expand its pipeline while reducing R&D spending by 25% compared to three years ago, indicating improved productivity within the organization [2]